CHA Medical Group and PAREXEL Collaborate to Enhance Early Phase Clinical Research in Korea

PAREXEL International Corporation announced a collaboration with CHA Medical Group to enhance early phase clinical development in Korea. The alliance is designed to provide biopharmaceutical companies with services that leverage PAREXEL’s clinical research and regulatory expertise with CHA’s experience conducting early phase studies in Korea.

Read the full release here.